HK1137339A1 - Use of dll4 antagonists in treating local ischemic injury dll4 - Google Patents

Use of dll4 antagonists in treating local ischemic injury dll4

Info

Publication number
HK1137339A1
HK1137339A1 HK10101051.2A HK10101051A HK1137339A1 HK 1137339 A1 HK1137339 A1 HK 1137339A1 HK 10101051 A HK10101051 A HK 10101051A HK 1137339 A1 HK1137339 A1 HK 1137339A1
Authority
HK
Hong Kong
Prior art keywords
dll4
ischemic injury
antagonists
treating local
local ischemic
Prior art date
Application number
HK10101051.2A
Other languages
English (en)
Chinese (zh)
Inventor
Stanley J Wiegand
Nicholas J Papadopoulos
Ivan B Lobov
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1137339A1 publication Critical patent/HK1137339A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK10101051.2A 2006-08-07 2010-01-29 Use of dll4 antagonists in treating local ischemic injury dll4 HK1137339A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83600306P 2006-08-07 2006-08-07
PCT/US2007/017546 WO2008019144A2 (en) 2006-08-07 2007-08-07 Threapeutic methods for treating vascular eye disorders with dll4 antagonists

Publications (1)

Publication Number Publication Date
HK1137339A1 true HK1137339A1 (en) 2010-07-30

Family

ID=38904599

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10101051.2A HK1137339A1 (en) 2006-08-07 2010-01-29 Use of dll4 antagonists in treating local ischemic injury dll4

Country Status (33)

Country Link
US (1) US20080181893A1 (xx)
EP (1) EP2054082B1 (xx)
JP (1) JP5529536B2 (xx)
KR (1) KR101497355B1 (xx)
CN (1) CN101500605B (xx)
AU (1) AU2007281916B2 (xx)
BR (1) BRPI0716424B8 (xx)
CA (1) CA2660235C (xx)
CO (1) CO6150190A2 (xx)
CR (1) CR10627A (xx)
DK (1) DK2054082T3 (xx)
ES (1) ES2398253T3 (xx)
GT (1) GT200900029A (xx)
HK (1) HK1137339A1 (xx)
HR (1) HRP20130271T1 (xx)
IL (1) IL196612A (xx)
MA (1) MA30667B1 (xx)
ME (1) ME00591B (xx)
MX (1) MX2009000674A (xx)
MY (1) MY150092A (xx)
NO (1) NO341857B1 (xx)
NZ (1) NZ574794A (xx)
PL (1) PL2054082T3 (xx)
PT (1) PT2054082E (xx)
RS (1) RS52685B (xx)
RU (1) RU2429876C2 (xx)
SG (1) SG174033A1 (xx)
SI (1) SI2054082T1 (xx)
SV (1) SV2009003161A (xx)
TN (1) TN2009000036A1 (xx)
UA (1) UA95304C2 (xx)
WO (1) WO2008019144A2 (xx)
ZA (1) ZA200900337B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
JP2010517944A (ja) * 2007-01-26 2010-05-27 バイオインヴェント インターナショナル アーベー Ｄｌｌ４シグナリング阻害薬およびその使用
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
BRPI0913476A2 (pt) * 2008-09-10 2015-12-01 Genentech Inc "usos de um antagonista tspan12 e usos de um antagonista de norrin"
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
WO2011008641A1 (en) 2009-07-13 2011-01-20 Beth Israel Deaconess Medical Center, Inc. Methids of modulating angiogenesis and treatment of angiogenesis-related diseases
JP5903382B2 (ja) 2009-08-29 2016-04-13 アッヴィ・インコーポレイテッド 治療用ｄｌｌ４結合タンパク質
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
CN105037543B (zh) * 2010-03-02 2020-11-03 Abbvie 公司 治疗性dll4结合蛋白
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
WO2014062659A2 (en) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Methods of treating ocular diseases
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
US11679126B2 (en) 2016-11-17 2023-06-20 Chldren's Medical Center Corporation Methods to enhance microvascular engraftment of bioengineered and primary tissues
WO2023063842A1 (ru) 2021-10-12 2023-04-20 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
JP2009507796A (ja) * 2005-09-01 2009-02-26 バスジーン セラピューティクス， インコーポレイテッド デルタ様リガンド４のモジュレーターの利用及び同定方法
RU2008152435A (ru) * 2006-06-06 2010-07-20 Дженентек, Инк. (Us) Композиции и способы регулирования развития сосудов

Also Published As

Publication number Publication date
BRPI0716424B8 (pt) 2021-05-25
KR101497355B1 (ko) 2015-03-02
JP2010500355A (ja) 2010-01-07
CO6150190A2 (es) 2010-04-20
KR20090039823A (ko) 2009-04-22
NO20090984L (no) 2009-03-04
UA95304C2 (ru) 2011-07-25
WO2008019144A2 (en) 2008-02-14
NO341857B1 (no) 2018-02-12
CN101500605A (zh) 2009-08-05
IL196612A (en) 2012-02-29
JP5529536B2 (ja) 2014-06-25
CR10627A (es) 2009-04-14
SI2054082T1 (sl) 2013-04-30
DK2054082T3 (da) 2013-01-21
CA2660235C (en) 2015-09-22
MY150092A (en) 2013-11-29
AU2007281916B2 (en) 2012-06-28
ES2398253T3 (es) 2013-03-14
MX2009000674A (es) 2009-02-04
WO2008019144A3 (en) 2008-03-27
BRPI0716424B1 (pt) 2018-06-26
ME00591A (en) 2011-12-20
TN2009000036A1 (en) 2010-08-19
ZA200900337B (en) 2009-12-30
MA30667B1 (fr) 2009-08-03
RS52685B (en) 2013-08-30
EP2054082A2 (en) 2009-05-06
EP2054082B1 (en) 2012-12-26
CN101500605B (zh) 2014-04-30
GT200900029A (es) 2009-11-17
PT2054082E (pt) 2013-03-07
AU2007281916A1 (en) 2008-02-14
RU2009107921A (ru) 2010-09-20
NZ574794A (en) 2011-06-30
RU2429876C2 (ru) 2011-09-27
IL196612A0 (en) 2011-08-01
BRPI0716424A2 (pt) 2014-05-20
HRP20130271T1 (hr) 2013-04-30
SV2009003161A (es) 2010-02-01
ME00591B (me) 2011-12-20
SG174033A1 (en) 2011-09-29
PL2054082T3 (pl) 2013-05-31
US20080181893A1 (en) 2008-07-31
CA2660235A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
HK1137339A1 (en) Use of dll4 antagonists in treating local ischemic injury dll4
PL2468290T3 (pl) Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
SI2120999T1 (sl) FARMACEVTSKI SESTAVKI, KI VSEBUJEJO AKTIVIN-ActRIIA ANTAGONISTE IN NJIHOVA UPORABA PRI PREPREÄŚEVANJU ALI ZDRAVLJENJU MULTIPLEGA MIELOMA
HK1151218A1 (en) Notch-binding agents and antagonists and methods of use thereof notch-
HK1207576A1 (en) Vla-1 antagonist for use in treating stroke vla-1
HK1142777A1 (en) Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma lingo-1 trkb
HK1199833A1 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer -actriia
GB2443823B (en) Devices and methods for use in construction
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
IL191810A (en) Dll4 antagonists and vegf inhibitor and their use in tumor development or growth methods
ZA200909059B (en) Hydrocarbon mixtures and use thereof
HK1146596A1 (en) Use of lingo-4 antagonists in the treatment of conditions involving demyelination lingo-4
EP2198869A4 (en) THERAPEUTIC OR PROPHYLACTIC AGENT FOR VASOCONSTRICTION
PL2315773T3 (pl) Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy
EP2307052A4 (en) ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE
IL201886A0 (en) Thromboxane receptor antagonist formulations for use in treating and preventing thrombosis
IL205207A0 (en) Benzimidazole derivatives and their use as fxr agonists
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
HRP20220346T3 (hr) Antagonist glp-1 receptora za upotrebu u liječenju kongenitalnog hiperinzulinizma
EP2119708A4 (en) TETRAHYDROQUINAZOLINE COMPOUNDS AND THEIR USE IN THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT AND PREVENTION OF VIROSES
IL200032A (en) Dopamine agonist for use in the treatment or prevention of endometriosis
EP2121785A4 (en) SYDNONIMINES - INHIBITORS FOR SPECIFIC DOPAMINE REABSORPTION AND THEIR USE IN THE TREATMENT OF DOPAMINE-RELATED DISORDERS
HK1172547A1 (en) Activin-actrii antagonists for use in treating anemia -actrii
GB0602744D0 (en) Amine and its therapeutic use